GlassScriptPhysician profile
Nancy C Rosenblatt
NPI 1962580399
$921.48
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $85.37 · 2021: $140 · 2022: $296.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $165.92 | 2019-2022 | |
| Alkermes, INC. | $159.02 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $133.96 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $99.04 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $94.70 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.07 | 2021-2022 | |
| Abbvie INC. | $62.33 | 2022 | |
| Lundbeck LLC | $47.66 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $33.17 | 2019-2020 | |
| Shire North American Group INC | $29.16 | 2019 | |
| Allergan, INC. | $16.45 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Rosenblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.